The United States government has canceled a contract with Emergent BioSolutions, a major vaccine manufacturer that came under investigation after it was blamed for a bad batch of 15 million doses of Johnson & Johnson’s COVID-19 vaccine.
The Department of Health and Human Services and Emergent mutually agreed to end the contract on Nov. 1, the Maryland-based company said in an earnings report.
The cancellation means the contract was reduced by about $180 million.
The contract was reached in June 2012. It included manufacturing therapies for cancer and tuberculosis vaccines. In 2020, it was expanded to include manufacturing for third-party COVID-19 vaccines and therapeutics.
But Emergent’s work on a batch of drug substances for the Johnson & Johnson vaccine was pinpointed as ruining some 15 million doses. Workers there mixed up ingredients for J&J’s shot and a vaccine from AstraZeneca.
The cancellation means the contract was reduced by about $180 million.
The contract was reached in June 2012. It included manufacturing therapies for cancer and tuberculosis vaccines. In 2020, it was expanded to include manufacturing for third-party COVID-19 vaccines and therapeutics.
But Emergent’s work on a batch of drug substances for the Johnson & Johnson vaccine was pinpointed as ruining some 15 million doses. Workers there mixed up ingredients for J&J’s shot and a vaccine from AstraZeneca.
Rose Rambles... 